BLTE

Belite Bio Inc

Add to Watchlist

Advanced Chart

61.330

+0.220(+0.360%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

62.260

Open

61.870

VWAP

60.57

Vol

21.36K

Mkt Cap

1.98B

Low

59.620

Amount

1.29M

EV/EBITDA(TTM)

Total Shares

29.79M

1.83B

EV/OCF(TTM)

P/S(TTM)

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. The Company is developing LBS-008 as an oral daily treatment for STGD1 and dry AMD. LBS-008 is a therapy targeting dry AMD and STGD1, which are untreatable conditions that cause progressive vision loss in affected individuals. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye. The Company's LBS-009 is an anti-Retinol binding protein 4 (RBP4) oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

-0.365

+35.19%

-0.360

+16.13%

-0.362

+29.46%

Estimates Revision

The market is revising No Change the revenue expectations for Belite Bio, Inc (BLTE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 14.00%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+12.06%

In Past 3 Month

Stock Price

Go Up

+14.00%

In Past 3 Month

4 Analyst Rating

57.62% Upside

Wall Street analysts forecast BLTE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLTE is 96.67 USD with a low forecast of 80.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

57.62% Upside

Current: 61.330

Low

80.00

Averages

96.67

High

110.00

57.62% Upside

Current: 61.330

Low

80.00

Averages

96.67

High

110.00

Benchmark

Bruce Jackson

Strong Buy

Reiterates

$80

2025-03-26

Reason

Benchmark

Bruce Jackson

Price Target

$80

2025-03-26

Reiterates

Strong Buy

Reason

Benchmark raised the firm's price target on Belite Bio to $80 from $79 and keeps a Buy rating on the shares. In February, Belite received a positive report from an interim data analysis of the Phase 3 DRAGON trial and a DSMB recommendation to seek accelerated regulatory approval, notes the analyst, who calls out completion of the DRAGON II study around mid-year and completion of the DRAGON study by year-end 2025 as the next major catalysts for the shares.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$100

2025-03-18

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$100

2025-03-18

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Jennifer Kim

Buy

Reiterates

n/a

2025-03-18

Reason

Cantor Fitzgerald

Jennifer Kim

Price Target

n/a

2025-03-18

Reiterates

Buy

Reason

Benchmark

Bruce Jackson

Strong Buy

Maintains

$57 → $79

2025-01-21

Reason

Benchmark

Bruce Jackson

Price Target

$57 → $79

2025-01-21

Maintains

Strong Buy

Reason

Benchmark raised the firm's price target on Belite Bio to $79 from $57 and keeps a Buy rating on the shares. After speaking to management at a conference last week, the firm revisited its pricing assumptions for Tinlarebant in the treatment of Stargardt disease type 1 and now assumes an average price of $50,000, the analyst tells investors.

Maxim Group

Jason McCarthy

Strong Buy

Maintains

$60 → $110

2024-11-15

Reason

Maxim Group

Jason McCarthy

Price Target

$60 → $110

2024-11-15

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$60 → $100

2024-11-13

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$60 → $100

2024-11-13

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Belite Bio Inc (BLTE.O) is -54.81, compared to its 5-year average forward P/E of -34.02. For a more detailed relative valuation and DCF analysis to assess Belite Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-34.02

Current PE

-54.81

Overvalued PE

-23.52

Undervalued PE

-44.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.22

Current PS

198.99

Overvalued PS

36.07

Undervalued PS

-25.63